Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn ’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

In the original publication of this article, the following correction should be noted in Table  5.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research

Related Links:

DiscussionAs the first trial to assess the effectiveness, safety and cost-effectiveness of TDM in patients receiving TNFi for a range of immune mediated inflammatory diseases, we hope that the NOR-DRUM study will contribute to the advancement of evidence based personalised treatment with biological medicines.Trial,NCT03074656. Registered on 090317.
Source: Trials - Category: Research Source Type: clinical trials
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2)
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
ConclusionThe safety profile of adalimumab was consistent with previous findings and no new safety signals were observed.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Ustekinumab, a monoclonal antibody that targets interleukin (IL)-12/23, is used to treat psoriasis, psoriatic arthritis and Crohn disease. In 2011, a meta-analysis of randomized trials alerted on a potential risk of major adverse cardiovascular events (MACE) within the first months after the initiation of anti-IL-12/23 antibodies. Our objective was to assess if ustekinumab initiation may trigger MACE. Using the French National Health Insurance database, covering 66 million subjects, we included all patients exposed to ustekinumab between 2010 and 2016, classified according to their cardiovascular risk level (high vs.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research and Epidemiology Source Type: research
We describe the case of a 37-year-old man with a 20-year history of psoriatic arthritis. The patient presented with abdominal pain, watery diarrhea with mild hematochezia, and a reported 24-pound unintentional weight loss over the past five months. Of note, the patient began treatment with etanercept five months earlier after discontinuation of infliximab for his psoriatic arthritis symptoms. Colonoscopy with terminal ileum intubation revealed active colitis and intestinal biopsy results showed marked ulcerations and non-caseating granulomas, indicative of CD. Etanercept was subsequently discontinued and the patient was st...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
CONCLUSION: Based on our systematic review, the epidemiology of IMIDs among immigrants varies according to native and host countries, immigrant generation, and IMID type. The rapid evolution suggests a role for non-genetic factors and gene-environment interactions. Future studies should focus on these pattern shifts, given implications of rising global burden of IMIDs and immigration. PMID: 31351784 [PubMed - as supplied by publisher]
Source: Journal of Autoimmunity - Category: Allergy & Immunology Authors: Tags: J Autoimmun Source Type: research
This study evaluated the impact of the HUMIRA Complete Pro (HCPro) online prescription management system on the rate of abandonment and the time to first fill for patients prescribed adalimumab (ADA). A retrospective cohort analysis of patients initiating ADA treatment with or without use of the HCPro online prescription processing system was used to evaluate the impact of HCPro on treatment initiation outcomes.MethodsPatient-level data for patients with an ADA prescription processed through HCPro were mapped to Symphony Health claims for patients initiating ADA between January 2012 and January 2015. The sample included pa...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
This article summarizes the milestones in the development of risankizumab leading to this first approval for psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Background: Skin and soft tissue infections (SSTIs) often occur at a site of disruption in the epidermal layer, creating an entry point for infection. Biologic agents have been established in the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn ’s disease. The immunomodulating effects of biologics have been thought to predispose patients to SSTIs. Several guidelines recommend discontinuing this agent for 4 half-lives before surgery; however, given the lack of understanding of the real risk of infection associated with the use of these ag ents, it is difficult to ascertain if these guid...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Interventional Studies, Clinical and Patient Outcomes Research Source Type: research
We presented a new statistic T to use large public database as reference to reduce concern of potential population stratification. And the new statistic proposed here is effective to discover novel genome-wide significant loci with both small and large sample sizes. Author Contributions YW conceived the idea and developed the software. YL, MH, and XL contributed data analysis, generating tables and figures, and manuscript writing. YW, YL, MH, XL, YS, and LJ contributed the theoretical analysis and manuscript revision. MX helped support the GWAS datasets. YW, YL, MH, XL, MZ, JW, and MX contributed to scientific discussion...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Arthritis | Crohn's Disease | Drugs & Pharmacology | Psoriasis | Psoriatic Arthritis | Rheumatology | Stelara